GENOSKIN

Revolutionizing Skin Cancer Diagnosis with Wearable Bioelectronics! We are thrilled to highlight an innovative study by our client at Karolinska Institutet showcasing a breakthrough in skin cancer diagnostics using a wearable bioelectronic patch for transdermal sensing of melanoma biomarkers. Their research showcases the potential of wearable bioelectronics in revolutionizing melanoma detection. By utilizing Genoskin's advanced human skin models, they've developed a microneedle patch capable of accurately sensing the melanoma biomarker, tyrosinase. This innovative approach marks a significant step forward in early-stage cancer diagnosis. Key highlights include: 👉 Sensing: The microneedle sensor allows for non-invasive, real-time monitoring of Tyr levels directly from the skin. 👉 Ex Vivo Human Skin Models: Utilizing NativeSkin® models, the study ensured realistic and accurate testing conditions, paving the way for clinical applications. 👉 Wearable Technology: The device offers a minimally disruptive means for continuous surveillance and timely intervention of skin anomalies, with potential applications extending to other skin conditions like inflammatory skin diseases and allergies. This groundbreaking approach could revolutionize skin health monitoring, providing clinicians and patients with a reliable tool for early melanoma detection and personalized healthcare. Check out the full publication to dive deeper into the methodology and findings: https://lnkd.in/e6uCQAAu #WearableTech #Bioelectronics #SkinCancer #Melanoma #SkinCancerDiagnosis

🔬 Exploring Vaccine-Induced Immune Responses 🔬 We’re excited to spotlight the groundbreaking #research that our Scientist, Manon Scholaert, will be presenting at the 7th European Congress of Immunology 2024 in Dublin! Her presentation, titled “Multimodal and Longitudinal Single-Cell Analysis of Local Innate Immune Response to Vaccine in Ex Vivo Natural Human Skin Modules,” offers three critical takeaways: 1️⃣ Single-Cell Resolution: Utilizing HypoSkin® models, we’ve achieved unprecedented insights into mRNA vaccine-induced #immuneresponses at the injection site. 2️⃣ Spatial Imaging: MANTIS® technology reveals key activation and redistribution of antigen-presenting cells, providing insights into cell distribution in the skin following injection. 3️⃣ Innate Immunity Insights: Our findings show the pivotal role of dendritic cells, macrophage and mast cell clusters in responding to SARS-CoV-2 spike mRNA post-injection. Don't miss Manon's session on Monday, September 2nd, from 15:55 to 17:10 in Room 08, LIFFEY MEETING ROOM 2. Explore our research further and discover how these insights are shaping the future of #vaccinedevelopment. For more information on our research 👉 https://lnkd.in/eHU87x7n

🎥 Unlock the Secrets of Vaccine Response! Join our Chief Scientific Officer, Dr. Nicolas Gaudenzio, as he guides you through our groundbreaking research:"Multimodal profiling of biostabilized human skin modules reveals a coordinated ecosystem response to injected mRNA-1273 COVID19 vaccine”, published in Allergy EAACI. In this video, Nicolas breaks down how our innovative ex vivo human skin models reveal the intricate dance of the immune system when exposed to the mRNA-1273 COVID-19 vaccine. It’s a must-watch for anyone interested in vaccine research. 👉Dive into the science and watch the full video here: https://lnkd.in/eTjHyzBq #VaccineResearch #Immunology #COVID19Vaccine #Genoskin #ScientificInnovation

We're #hiring a new Group Manager - Senior Scientist in Salem, Massachusetts. Apply today or share this post with your network.

What if you could predict injection site pain without injecting into a human subject? How can a human skin model lacking nerve endings be used to predict pain and injection site reaction? 👉🏻https://lnkd.in/dzbhUW35 #Neuroinflammation #DrugDevelopment #Biotech #Pharma #Innovation #PatientSafety #injection

Uncover the techniques that could transform your next breakthrough for your drug development efforts! 💉 Explore how understanding of pain and neurogenic inflammation can be leveraged to predict and mitigate injection-related pain. 🧪Discover how transcriptomics is transforming vaccine development, offering unprecedented insights into the immune system and leading to more effective and targeted vaccines. ...and that's just the beginning! Our blog breaks down these complex topics and shows you how to leverage these insights for a competitive edge. Don't miss out! https://lnkd.in/e8UQeE5T

🚨 Exciting News from Genoskin! 🚨 We’re thrilled to announce that our Scientist, Manon Scholaert, will be presenting her cutting-edge #research at the European Congress of Immunology (ECI) 2024 in Dublin! 🌍✨ 🗓 Mark your calendars for Monday, September 2nd, from 15:55 to 17:10. Join us in Room 08, LIFFEY MEETING ROOM 2, for Session WS26 - Immunology of Skin Disease, where Manon will dive into "Multimodal and Longitudinal Single-Cell Analysis of Local Innate Immune Response to Vaccine in Ex Vivo Natural Human Skin Modules." Also attending will be our Chief Scientific Officer, Dr. Nicolas Gaudenzio. Don't miss this opportunity to explore innovative approaches to skin #immunology! For more information on our research 👉 https://lnkd.in/eafC_CP8

🧬 Key Insights from Genoskin's Latest Research 🧬 We are excited to share some of the major findings from our newly published study in Allergy EAACI: 1️⃣ We developed a versatile framework for longitudinal profiling of the human skin ecosystem in response to vaccines at the injection site, using a matrix-skin biopsy-silicone ring association that allows for subcutaneous or intradermal delivery while preserving native adipose tissue integrity. 2️⃣ At the organ level, the study deciphered precise sequential events following vaccine injection, including recognition and response to foreign agents, adjustments in skin homeostasis, activation of stress responses, and initiation of immune reactions. 3️⃣ At the single-cell level, the mRNA-1237 COVID-19 vaccine consistently targeted dermal DC/macrophages and mast cells, regardless of the administration route, and triggered substantial transcriptomic changes in the entire myeloid compartment and a significant proportion of CD4 and CD8 T cells. These insights bring us closer to developing safer, more effective vaccines by deepening our understanding of skin immune responses to injected drugs. A huge thank you to our team and collaborators at Infinity - Toulouse Institute for Infectious and Inflammatory Diseases for their relentless pursuit of excellence in research! 🔗 https://lnkd.in/e7FmNYqi #VaccineResearch #ScientificInnovation #Genoskin #AllergyJournal

Are your therapeutic candidates reaching their full potential? Unlock the power of human-based data with Genoskin's testing services. At Genoskin, our mission is more than just providing services; we deliver solutions aligned with the 3Rs to help the pharmaceutical industry mitigate risks in the development of injectable therapeutics. Our approach delivers real insights into biological responses, enabling researchers to better anticipate clinical outcomes. Whether you're developing a topical, systemic, or injectable solution or you are working on therapeutics targeting mast cells or psoriasis, our various platforms offer the accuracy and insights you need. 🌟 Why Choose Our Platforms? 🔬 NativeSkin access®: Perfect for both topical and systemic-like applications, ensuring comprehensive efficacy and barrier function assessments. 💉 HypoSkin®: The go-to for injectable applications, delivering unmatched insights into immunotoxicity, tolerability, and responses to vaccines. 🧫 InflammaSkin®: Dive deep into T cell activation and immune psoriasiform phenotypes, providing critical data on efficacy. 🧬 Primary Mast Cells: Harness the power of human primary cells in vitro to evaluate both efficacy and toxicity with precision. Rely on early human data for your safety and local toxicity assessment. Visit our website now to learn more 👉🏻https://lnkd.in/euAXv-dC #DrugDevelopment #Vaccines #DrugEfficacy #Psoriasis #SafetyAssessment #Toxicity #MastCells

Did you know that psoriasis affects over 125 million people worldwide, impacting their quality of life and overall health? As we recognize Psoriasis Awareness Month this August, it's crucial to highlight the ongoing battle against this chronic autoimmune condition and the advancements in therapeutic solutions. At Genoskin, we are committed to supporting the development of innovative anti-psoriasis treatments. Our InflammaSkin® platform is designed to accelerate the journey from research to patient relief, ensuring that promising therapies reach those in need faster. Join us in raising awareness and making a difference. Explore our advanced psoriasis testing solutions today and see how we can collaborate to drive progress in psoriasis care. 👉🏻https://bit.ly/46Vnn56 #DrugDevelopment #psoriasis #exvivo #skin #innovation